盐酸缬更昔洛韦片怎么样？

It is an oral anti-cytomegalovirus infection drug developed by the Swiss company Roche. Its main ingredient is valganciclovir hydrochloride. Valganciclovir is the L-valyl ester (prodrug) of ganciclovir, which is rapidly converted into ganciclovir by esterases in the small intestine and liver after oral administration. Ganciclovir is a synthetic 2'-deoxyguanosine analog that inhibits herpes virus replication in vitro and in vivo. Susceptible human viruses include human cytomegalovirus (HCMV), herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV), and hepatitis B virus.

In cells infected with cytomegalovirus (CMV), ganciclovir is first phosphorylated by the viral protein kinase UL97 to ganciclovir monophosphate. It is further phosphorylated by intracellular protein kinases into ganciclovir triphosphate, which is then slowly metabolized within the cell. After removal of extracellular ganciclovir, the observed half-life of ganciclovir in HSV- or HCMV-infected cells was 18 hours (6-24 hours), respectively. Since the phosphorylation process relies heavily on viral protein kinases, ganciclovir phosphorylation occurs preferentially in virus-infected cells.

Clinically, Valganciclovir Hydrochloride Tablets are mainly used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis. What about Valganciclovir Hydrochloride Tablets?

Clinical studies of valganciclovir hydrochloride tablets in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with valganciclovir hydrochloride tablets 900 mg per day. The mean (median) time from randomization to progression of CMV retinitis was 226 (160) days and 219 (125) days in patients who received induction or intravenous ganciclovir followed by maintenance therapy with valganciclovir hydrochloride tablets, respectively.